Patent · US Expired

Substituted pyrazoles as p38 kinase inhibitors

US7153959B2 · kind B2 · utility

3Cited by

17References

9Claims

0Family size

Assignee

Pharmacia Corporation · SE

Inventors

Ashok S. Naraian · Ballwin, US
Michael Clare · Skokie, US
Paul W. Collins · Deerfield, US
Joyce Z. Crich · Glenview, US
Rajesh Devraj · Chesterfield, US
Daniel L. Flynn · Lawrence, US
Lifeng Geng · Skokie, US
Matthew J. Graneto · Chesterfield, US
Cathleen Hanau · Chesterfield, US
Gunnar J. Hanson · Cambridge, US
Susan J. Hartmann · Kirkwood, US
Michael Hepperle · Boston, US
He Huang · Northbrook, US
Francis J. Koszyk · Prospect Heights, US
Shuyuan Liao · Northbrook, US
Suzanne Metz · Chesterfield, US
Richard A. Partis · Evanston, US
Thao Perry · San Jose, US
Shashidhar N. Rao · Chesterfield, US
Shaun Raj Selness · Chesterfield, US
Michael S. South · Chesterfield, US
Michael A. Stealey · Libertyville, US
John J. Talley · Chesterfield, US
Michael L. Vazquez · Saint Louis, US
Richard M. Weier · Lake Bluff, US
Xiangdong Xu · Gurnee, US
Ish Khanna · Vernon Hills, US
Yi Yu · Skokie, US
Win Naing · Chesterfield, US
Syaulan Yang · Zhubeikou, TW

Key dates

Filing date	Feb 25, 2003
Grant date	Dec 26, 2006
Priority date	—
Expiry date	Aug 3, 2023

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07D487/04
WIPO fieldOrganic fine chemistry
WIPO sectorChemistry

Abstract

A class of pyrazole derivatives is described for use in treating p38 kinase mediated disorders. Compounds of particular interest are defined by Formula IA

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.